|

Anifrolumab Clinical Trials

8 actively recruiting trials across 4 locations

Also known as: (MEDI-546), Saphnelo

Pipeline

Phase 2: 1Phase 3: 1Phase 4: 1

Top Sponsors

  • AstraZeneca7
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)1

Indications

  • Lupus8
  • Systemic Lupus Erythematosus6
  • Lupus Erythematosus, Systemic2
  • Premature Atherosclerosis1
  • Cardiovascular Disease1

Other4 trials

Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.
Anifrolumab Malignancy and Serious Infections Study
Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus
The Anifrolumab PRIM Program

Phoenix, Arizona1 trial

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

Research Site

Phase 3

Bethesda, Maryland1 trial

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

National Institutes of Health Clinical Center

Phase 2

Las Vegas, Nevada1 trial

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

Research Site

Phase 4

Wilmington, North Carolina1 trial

Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

Research Site

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.